Anika Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Anika Therapeutics is a global joint preservation company serving osteoarthritis pain management, regenerative solutions, sports medicine, and Arthrosurface joint-replacement markets. The filing covers the quarter and six months ended June 30, 2023; results are unaudited and should be read with the 2022 Form 10-K.
The company reports one operating and reportable segment. Its principal product families are OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic products.
Financial Performance and Liquidity
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $44.3 million, up 12% | $82.2 million, up 8% |
| Gross profit | $29.0 million, up 17% | $51.8 million, up 11% |
| Gross margin | 65%, versus 63% | 63%, versus 61% |
| Operating loss | $3.6 million, versus $3.4 million | $16.2 million, versus $6.9 million |
| Net loss | $2.7 million, or $0.19 per diluted share | $13.1 million, or $0.89 per diluted share |
| Adjusted EBITDA | $6.3 million, versus $4.4 million | $5.1 million, versus $7.0 million |
Revenue growth was led by OA Pain Management, which increased 22% in the quarter and 15% year to date, and Joint Preservation and Restoration, which increased 5% and 8%, respectively. Non-Orthopedic revenue declined 33% in the quarter and 41% year to date.
Research and development expense increased 28% in the quarter and 32% year to date, primarily due to regulatory compliance and new product development. Selling, general and administrative expense increased 11% in the quarter and 25% year to date, including non-recurring costs related to the Parcus arbitration settlement, shareholder activism, and other corporate matters.
Cash and cash equivalents were $65.1 million at June 30, 2023, compared with $86.3 million at December 31, 2022. Working capital was $128.7 million, compared with $141.6 million at year-end. The company had no outstanding borrowings under its $75.0 million revolving credit facility and stated that it was in compliance with the facility.
Operating activities used $11.9 million of cash in the first six months, compared with $1.2 million provided in the prior-year period. Investing activities used $2.8 million, principally for property and equipment. Financing activities used $6.6 million, including $5.0 million for share repurchases. Inventory was $42.6 million, net of approximately $10.2 million of reserves.
Material Changes Versus the Prior Comparable Period
- Revenue increased $4.6 million in the quarter and $5.9 million year to date, with growth concentrated in OA Pain Management and Joint Preservation and Restoration.
- Gross margin improved by two percentage points in both reported periods due primarily to product mix, higher Mitek sales, and improved production volumes.
- Year-to-date operating loss increased by $9.2 million and net loss increased by $7.3 million, primarily reflecting higher operating expenses and non-recurring corporate costs.
- The company paid approximately $8.5 million of non-recurring costs during the first six months, including the Parcus arbitration settlement, shareholder activism, and other corporate costs.
- The company entered into a $20.0 million share repurchase program. During the quarter it repurchased $5.0 million of stock through an accelerated share repurchase arrangement; an additional 29,046 shares were received upon final settlement in July 2023.
- Revenue classification was revised so veterinary product sales are reported in Non-Orthopedic rather than OA Pain Management for all periods presented.
- On June 14, 2023, stockholders approved an increase of 435,000 shares available under the 2017 equity incentive plan.
Guidance, Outlook, Risks, and Unusual Items
Management expects to incur an operating loss for 2023 and expects continued investment in research and development, commercial capabilities, and operational infrastructure. The filing does not provide specific full-year revenue, earnings, or cash-flow guidance.
Management believes cash on hand, future operating cash flows, and available credit capacity will fund anticipated operating needs, but states that additional equity or debt financing could be required if these resources are insufficient.
- Customer concentration is significant: DePuy Synthes Mitek Sports Medicine represented 48% of second-quarter revenue and 46% of year-to-date revenue.
- Cingal, Hyalofast, and certain other pipeline products require or await applicable regulatory approvals or clearances, and Cingal was not approved for commercial use in the United States as of the filing.
- The company disclosed material weaknesses in internal control over financial reporting. Disclosure controls were therefore concluded to be ineffective as of June 30, 2023; remediation was in process but not complete.
- The Parcus Medical earnout arbitration was settled in April 2023. The company recorded a $3.3 million charge and liability at March 31, 2023 and paid the amount in April.
- Domestic deferred tax assets became subject to a valuation allowance because the company expects a 2023 operating loss and has current and prior-year losses.
- Industry risks include regulatory approval requirements, product development and commercialization risk, competition, protection of intellectual property, dependence on key personnel, customer concentration, inventory reserves, and foreign-currency exposure.
Most Important Facts to Verify
- Whether revenue growth in OA Pain Management and Joint Preservation and Restoration continues to offset weakness in Non-Orthopedic products.
- The duration and financial impact of ongoing operating losses and negative operating cash flow.
- Remaining authorization and execution of the $20.0 million share repurchase program and its effect on liquidity.
- Progress in remediating the disclosed material weaknesses in internal control over financial reporting.
- Regulatory timing and commercialization prospects for Cingal, Hyalofast, and the regenerative product pipeline.
- Reliance on DePuy Synthes Mitek Sports Medicine and the potential impact of changes in its ordering patterns.
- Whether inventory levels and approximately $10.2 million of inventory reserves result in future write-downs or margin pressure.